Updates on Obesity Treatment:

Slides:

Advertisements

Similar presentations

Experimental Trials. Oslin ExTENd Late Trigger for Nonresponse 8 wks Response TDM + Naltrexone CBI Random assignment: CBI +Naltrexone Nonresponse Early.

Advertisements

Beyond Dieting: New Weight Loss Medications & Treatments on the Horizon Daniel Bessesen, MD.

Medical Management of obesity Perinatal ANGELS Conference Feb 17, 2005 Philip A. Kern.

VA/DoD 2006 Clinical Practice Guideline For Screening and Management of Overweight and Obesity Guideline Summary: Key Elements.

Investigation 5-2 Did the prevention strategy work? xxxxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxx.

CDA exercise guidelines 150 minutes moderate – intensity (60 – 70% of max) aerobic over minimum 3 non consecutive days PLUS resistance exercise 3.

Overweight and Obesity: Validation as a Chronic Disease

Deciphering Obesity Management Guidelines

The Effect of Intra-Articular Steroids on Cartilage in Knee Osteoarthritis.

The Fight Against Obesity as a Disease: Tackling the Core of the Condition.

Making the Case for Metabolic Surgery in Patients With Obesity and T2DM.

Pharmacy Perspectives in Multiple Myeloma: Relapsed and/or Refractory Disease.

Pharmaceutical- vs Dispensary-Sourced Cannabinoids

Bipolar Disorder: Latest Clinical Update

The role of metabolic surgery in the management of obesity and t2dm

Exploring the Spectrum of Excessive Daytime Sleepiness

The "Metabolically Healthy Obese"

Updates on Emerging GLP-1 Receptor Agonists

Does One Size Fit All in Obesity Management?

Progression After Cancer Immunotherapy in Advanced NSCLC

Emergency Management of NOAC Bleeding

COPD Management.

Epidemiology Venous Pathophysiology Etiology.

What Comes Second?.

Achieving and Maintaining Weight Loss in Obesity: Clinical Evidence for Novel Approaches.

This Program Will Discuss

Advances in Dyslipidemia: What Have We Learned From ACC 2017

Managing Hereditary Angioedema

SGLT2 Inhibitors in Phase 3 Trials

Can Primary Care Physicians Take the Lead in Combating Obesity?

Case Challenges in Chronic Migraine

Panelists. Unique Perspectives on the Cost Burden of Diabetes in the United States.

Successful Obesity Management and Counseling:

Early Type 2 Diabetes Mellitus: A Cardiovascular Disease

Obesity Management Today:

Metabolically Healthy Patients With Obesity

Managing Depression in Bipolar I Disorder

Precision Management of RA and Comorbidities

Updates in Preventing Skeletal-Related Events in Multiple Myeloma

Pharmacist Perspectives on Novel Agents in Multiple Myeloma

Team-Based Perspectives on Successful Approaches in Treating Obesity

Growing Diabetes Pandemic Worldwide

Estimated Number of Cancer Cases (in Thousands) Attributable to Excess Body Mass

Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?

Advancing the Treatment of IBD With Biologics

Improving Outcomes in Psoriatic Arthritis

Goals. Weight Management Goals and Approaches in Patients With Type 2 Diabetes.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.

When Is Intrathecal Drug Delivery Appropriate?

Practical Challenges in Obesity: Is It Possible to Maintain Weight Loss?

Scientific Update.

Clinical Pearls on Hot Topics in MS

Case Challenges: Early and Intensive Type 2 Diabetes Treatment With Modern Agents.

THE TRUTH ABOUT MODERN OBESITY AGENTS: ARE THEY REALLY SAFE AND EFFECTIVE?

Obesity and Weight Loss: How Can Cross-Functional Collaboration and Integrated Care Work in Practice?

The Fight Against Obesity as a Disease: Tackling the Core of the Condition.

5 Good Minutes on Atrial Fibrillation-related Stroke

Selecting Treatment Approaches in Hemophilia

When Is Intrathecal Drug Delivery Appropriate?

Optimizing Outcomes for Patients With Systemic Lupus Erythematosus: Key Considerations.

Obesity Management.

VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.

Change in (A) total cholesterol; (B) LDL-cholesterol; (C) HDL-cholesterol and (D) triglycerides over 5 years in response to 12-week intensive lifestyle.

Change in %A1C over 5 years in response to 12-week intensive lifestyle intervention used in a real-world clinical practice. Change in %A1C over 5 years.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Change in (A) systolic blood pressure and (B) diastolic blood pressure over 5 years in response to 12-week intensive lifestyle intervention in a real-world.

MS, Age, and Immune Function

Percentage of weight loss over 5 years in response to 12-week intensive lifestyle intervention in a real-world clinical practice. Percentage of weight.

PCSK9 Inhibitors and Real-World Evidence

Embracing Obesity in Collaboration -- Why, When, and How to Intervene

Presentation transcript:

Updates on Obesity Treatment:

Program Goals

Progress in Obesity Management and Treatment

Obesity-Associated Conditions and Complications

Recent Guidelines for Obesity Management

Drugs FDA-Approved for Long-term Use in Weight Loss/Weight Management

Importance of Diet and Lifestyle Changes

FDA Efficacy Benchmarks for Weight Loss Products

Predicting Response to Lorcaserin: Weight Loss at 52 Weeks

COR-BMOD Trial: Impact of Intensive Behavior Modification with or without Naltrexone SR/Bupropion SR (32 mg/d)

Response vs Nonresponse to Weight Loss Medications

Setting Weight Loss Expectations

Comorbid Conditions Improved by Weight Loss in Obese Individuals

Obesity Medicine: A New Subspecialty

Individualizing Treatment Selection Based on Comorbidities/Coexisting Conditions: Examplesa,b

Maintaining Weight Loss

Summary and Closing Comments

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)